Cosme Lozano, MD
Psychiatry · Joliet, ILNPI 1336160597
Payments from drug & device makers
Across 354 payments — averaging $1939.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$580K
- Livanova USA, Inc.$68K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$18K
- Supernus Pharmaceuticals, Inc.$9K
- AbbVie$8K
- Johnson & Johnson$541
- plus $4K from 26 others
What the payments were for
- Food & beverage$4,50995%
- Education$2315%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 41 | $579,789 |
| Livanova USA, Inc. | 33 | $68,344 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $17,826 |
| Supernus Pharmaceuticals, Inc. | 2 | $8,950 |
| AbbVie(2 entities) | 23 | $7,570 |
| Johnson & Johnson | 31 | $541 |
| Otsuka America Pharmaceutical, Inc. | 39 | $539 |
| Teva Pharmaceuticals USA, Inc. | 14 | $458 |
| Vanda Pharmaceuticals Inc. | 17 | $342 |
| Lundbeck LLC | 24 | $320 |
| Neurocrine Biosciences, Inc. | 17 | $312 |
| Alkermes, Inc. | 15 | $302 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $243 |
| Sunovion Pharmaceuticals Inc. | 14 | $220 |
| Axsome Therapeutics, Inc. | 6 | $162 |
| Shire North American Group Inc | 8 | $148 |
| Avanir Pharmaceuticals, Inc. | 5 | $116 |
| Indivior Inc. | 4 | $69 |
| Almatica Pharma LLC | 3 | $51 |
| Acadia Pharmaceuticals Inc | 3 | $46 |
| Bausch Health US, LLC | 3 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Adlon Therapeutics L.p. | 2 | $36 |
| Ironshore Pharmaceuticals Inc. | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Neuronetics, Inc. | 1 | $27 |
| Corium, LLC | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Rhodes Pharmaceuticals L.p. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| OWP Pharmaceuticals, Inc. | 1 | $3 |
How this compares
$686,665 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 54 | $192,317 |
| AustedoDeutetrabenazine | 12 | $84,164 |
| Wellbutrin XlBupropion Hcl | 13 | $51,956 |
| Abilify MaintenaAripiprazole | 17 | $49,454 |
| Lurasidone Hcl | 165 | $31,800 |
| Clozapine | 109 | $14,874 |
| Divalproex Sodium ErDivalproex Sodium | 357 | $13,994 |
| Risperdal ConstaRisperidone Microspheres | 22 | $13,968 |
| Paliperidone ErPaliperidone | 72 | $11,661 |
| Aripiprazole | 172 | $9,520 |
| Oxcarbazepine | 153 | $7,582 |
| Chlorpromazine Hcl | 44 | $5,660 |
| Risperidone | 677 | $5,244 |
| Adderall XrDextroamphetamine/Amphetamine | 12 | $4,782 |
| Quetiapine Fumarate | 305 | $4,548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $541 | $206,28576 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $458 | $84,16412 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $539 | $49,45417 claims |
| Almatica Pharma LLCSertraline Hcl | $51 | $1,580362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Joliet
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.